Clinical trials: Wet Macular Degeneration
Wet Age-related Macular Degeneration
This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD
The purpose of this study is to compare the efficacy and safety of SCT510A versus Lucentis in the treatment of wet age-related macular degeneration.
- Trial name
- NCT05480293
- Testing
- Ranibizumab, SCT510A
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Sinocelltech Ltd.
Wet Age-related Macular Degeneration
A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)
This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of QL1207 compared to Eylea® in subjects with wet AMD.
- Trial name
- NCT05345236
- Testing
- Aflibercept
- Where
- China
- Volunteers
- 366 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Neovascular Age-related Macular Degeneration
Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD
To evaluate the safety and tolerability of suprachoroidally administered CLS-AX following intravitreal anti-VEGF therapy in subjects with neovascular age-related macular degeneration (AMD)
- Trial name
- OASIS (NCT04626128)
- Testing
- CLS-AX, Anti-VEGF
- Where
- 11 sites in United States
- Volunteers
- 27 people
- Sponsor
- Clearside Biomedical, Inc.
Neovascular Age-related Macular Degeneration
Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration
This clinical study is a phase 1 study which carried out to to evaluate the safety, pharmacokinetics and tolerability of multiple intravitreal injections of BCD-021(bevacizumab biosimilar candidate manufactured by CJSC BIOCAD…
- Trial name
- NCT02450981
- Testing
- Bevacizumab (BCD-021)
- Sponsor
- Biocad
Neovascular (wet) Age-Related Macular Degeneration
The Effect of Phacoemulsification on the Macular Changes in Patients with Neovascular Age-related Macular Degeneration
The macula has a very high concentration of photoreceptor cells - the cells that detect light. They send signals to the brain, which interprets them as images.
- Trial name
- it does not (NCT06759597)
- Volunteers
- 50 people
- Sponsor
- Assiut University
Wet Macular Degeneration
Optimizing the Treatment Strategy for Age-related Macular Degeneration
The purpose of this study is to compare two different treatment protocols for wet macular degeneration; the new protocol called "Observe and Plan" against the current standard protocol "Treat and Extend".
- Trial name
- OnP2 (NCT04420923)
- Testing
- Observe and Plan, Treat-and-Extend
- Where
- 3 sites in Norway
- Volunteers
- 250 people
- Sponsor
- St. Olavs Hospital
Diabetic Macular Edema, Age Related Macular Degeneration
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
Diabetic macular edema (DME), wet-AMD and macular edema secondary to vein occlusions are the leading cause of blindness in developed countries.
- Conditions
- Diabetic Macular Edema, Age Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With Macular Edema
- Trial name
- NCT02556723
- Testing
- Intravitreal injections of ziv-aflibercept
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Retina Clinic, Sao Paulo, Brazil
Submacular Hemorrhage, Wet Macular Degeneration
Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration
This study will define the limits of subretinal hemorrhage parameters that are consistent with a good visual outcome with aggressive anti-VEGF treatment in patients with neovascular age-related macular degeneration (NVAMD).
- Conditions
- Submacular Hemorrhage, Wet Macular Degeneration, Neovascular Age-related Macular Degeneration
- Trial name
- NCT03699618
- Testing
- Anti-VEGF, Hemorrhage displacement + Anti-VEGF
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Age Related Macular Degeneration (AMD)
Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration
The aim of this study is to test if PF582 (ranibizumab) is safe and similar to Lucentis (ranibizumab). Participants will have a screening visit to check for eligibility.
- Trial name
- NCT02121353
- Testing
- Lucentis, PF582
- Where
- 2 sites in New Zealand
- Volunteers
- 25 people
- Sponsor
- Pfenex, Inc
Age Related Macular Degeneration
Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes
Age Related Macular Degeneration (AMD) is the leading cause of blindness in North America. This condition causes a progressive loss of central vision, the part of your vision that allows you to read, drive and see images in sharp…
- Trial name
- NCT01363570
- Testing
- Ranibizumab
- Where
- 2 sites in Canada
- Volunteers
- 70 people
- Sponsor
- McMaster University
Age-related Macular Degeneration (AMD)
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
In this cross-sectional study of patients with wet AMD who received ≥1 anti-VEGF injection (excluding brolucizumab), evidence was generated to describe the period prevalence of specific ocular AEs.
- Trial name
- NCT05110209
- Testing
- Aflibercept, Ranibizumab, Bevacizumab
- Where
- United States
- Volunteers
- 331,541 people
- Sponsor
- Novartis Pharmaceuticals
Choroidal Neovascularization, Wet Macular Degeneration
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.
- Trial name
- DECO (NCT03452527)
- Testing
- ICON-1, aflibercept
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Iconic Therapeutics, Inc.
Neovascular Age-Related Macular Degeneration
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
To compare brolucizumab to aflibercept in Chinese patients with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)
- Trial name
- NCT04047472
- Testing
- Brolucizumab 6mg, Aflibercept 2 mg
- Where
- 30 sites in China
- Volunteers
- 397 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
This study is intended to assess safety, tolerability and biological activity of a repeat IVT injection of UBX1325 in patients with wet AMD.
- Trial name
- NCT05275205
- Testing
- UBX1325 injection 50 μL, EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- Unity Biotechnology, Inc.
Macular Degeneration
Correlation Between Visual Acuity Measurements, Quality of Life and Morphological Parameters in Wet AMD Patients
Patient-reported vision-related quality of life (QOL) outcomes are increasingly incorporated into clinical trials of new treatments for age-related macular degeneration (AMD).
- Trial name
- COSP (NCT03438669)
- Testing
- no intervention
- Where
- Switzerland
- Volunteers
- 53 people
- Sponsor
- Dr. med. Katja Hatz
Age Related Macular Degeneration
Retinal Pigment Epithelium Safety Study for Patients in B4711001
This is a safety follow-up study. Patients enrolled in B4711001 will be followed for a further 4 years with regular visits to assess safety.
- Trial name
- NCT03102138
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Neovascular Age-related Macular Degeneration
Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related…
- Trial name
- DRAGON (NCT01775124)
- Testing
- Ranibizumab
- Where
- 23 sites in China
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular (Wet) Age-related Macular Degeneration
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
This was a retrospective, observational cohort study. Data were analyzed from the Intelligent Research in Sight (IRIS) registry from October 8, 2019, through November 26, 2021, with a follow-up period of 12 months following the…
- Trial name
- NCT06184360
- Where
- United States
- Volunteers
- 2,079 people
- Sponsor
- Novartis Pharmaceuticals
Wet Age-related Macular Degeneration
Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD
This is a randomized, double-blind, two-group parallel, positive-controlled clinical Phase I trial comparing the safety, pharmacokinetics, pharmacodynamics and efficacy of CMAB818 and Lucentis® in patients with wet age-related…
- Trial name
- NCT04884399
- Testing
- CMAB818, Lucentis®
- Where
- 4 sites in China
- Volunteers
- 24 people
- Sponsor
- Shanghai Biomabs Pharmaceutical Co., Ltd.
Macular Degeneration
VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)
This study will assess the efficacy and safety of intravitreally (IVT), i.e. directly into the eye administered VEGF Trap-Eye compared with photodynamic therapy (PDT) on visual function in Chinese subjects with age-related…
- Trial name
- NCT01482910
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Visudyne
- Where
- 14 sites in China
- Volunteers
- 304 people
- Sponsor
- Bayer